Peer-reviewed veterinary case report
Canine atopic dermatitis improved by interferon gamma treatment
By Iwasaki, T. et al.·Published in Veterinary Dermatology·2004·View original on Crossref →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Effect of recombinant canine IFNγ on canine atopic dermatitis evaluated by clinical signs, histopathology and expression of Th1/Th2 cytokine mRNA
- Species:
- dog
Plain-English summary
A group of 10 dogs with atopic dermatitis (a skin condition causing itching and inflammation) received six injections of a treatment called recombinant canine interferon gamma (rCaIFNγ) over two weeks. After treatment, seven of the dogs showed improvement, with a decrease in certain immune markers and overall skin health. Nine out of ten dogs had lower levels of IgE, a substance linked to allergic reactions, and skin biopsies showed less inflammation. This suggests that rCaIFNγ could be a safe and effective option for treating atopic dermatitis in dogs by helping balance the immune response.
People also search for: dog atopic dermatitis treatment · rCaIFNγ for dogs · dog skin allergy symptoms
Abstract
Atopic dermatitis (AD) is thought to be caused by immunologic abnormalities expressed as a Th1/Th2 cytokine imbalance in both humans and dogs. Several studies have focused on the therapeutic effects of IFNγ in human AD with successful results; however, the mechanism of action of IFNγ is not fully understood. We investigated the effect of recombinant canine interferon gamma (rCaIFNγ) on 10 dogs with AD and evaluated the ratio of IL‐4 mRNA to IFNγ mRNA in peripheral blood mononuclear cells, serum total IgE levels, and histological changes in skin. After six injections of rCaIFNγ over a span of 2 weeks, seven of the 10 dogs showed improvement, and six of these seven dogs exhibited decreased IL‐4:IFNγ mRNA ratios. Two of the three cases that did not improve had increased IL‐4:IFNγ mRNA ratios. Total serum IgE levels were significantly decreased in nine of 10 cases. The number of IgE‐positive cells detected by immunostaining and the number of mast cells in skin biopsy samples were decreased. A reduction of epidermal cell layers was demonstrated by histopathology after treatment. These results demonstrated that rCaIFNγ may be a novel safe and effective therapeutic option for the treatment of canine AD, and the mechanism of action of rCaIFNγ may be related to the modulation of Th2 cytokines to Th1 cytokines with the reduction of serum IgE production. Funding: Self‐funded.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Crossref: https://doi.org/10.1111/j.1365-3164.2004.00410_1-10.x